<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03587415</url>
  </required_header>
  <id_info>
    <org_study_id>107</org_study_id>
    <nct_id>NCT03587415</nct_id>
  </id_info>
  <brief_title>Serum Preptin and Amylin Levels in Polycystic Ovary Syndrome Patients</brief_title>
  <official_title>Serum Preptin and Amylin Levels With Respect to Body Mass Index in Polycystic Ovary</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Recep Tayyip Erdogan University Training and Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Recep Tayyip Erdogan University Training and Research Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Preptin and amylin are pancreatic hormones which participate in glucose homeostasis. This
      study aims to evaluate how serum preptin and amylin levels are altered in polycystic ovary
      syndrome (PCOS) patients and healthy women based on BMI groups .
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Materials and Methods: This is a cross-sectional review of 40 PCOS patients and 40 healthy
      women who were matched with respect to BMI (&lt;25 kg/m2 and ≥25 kg/m2).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 28, 2017</start_date>
  <completion_date type="Actual">December 7, 2017</completion_date>
  <primary_completion_date type="Actual">November 30, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Serum Preptin and Amylin Levels with Respect to Body Mass Index in Polycystic Ovary Syndrome Patients</measure>
    <time_frame>six months</time_frame>
    <description>Serum Preptin and Amylin Levels will compare between groups</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">80</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>Polycyctic ovary sendrome (PCOS)</arm_group_label>
    <description>these women who have PCOS, we will use their blood samples</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healty groups</arm_group_label>
    <description>These women who have reguler menstrual cycle, no akne or hirsutism, we will use their boold samples</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>preptin and amylin level</intervention_name>
    <description>we will take both of group blood samples to compare them serum preptin and amylin</description>
    <arm_group_label>Healty groups</arm_group_label>
    <arm_group_label>Polycyctic ovary sendrome (PCOS)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Polycystic ovary syndrome
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        the patients with PCOS

        Exclusion Criteria:

        Cushing's syndrome 21-hydroxylase deficiency Congenital adrenal hyperplasia Thyroid
        dysfunction Hyperprolactinemia Diabetes Chronic cardiovascular Hepatic, renal, and
        hematologic diseases Malignancies Using oral contraceptives, anti-androgens,
        glucocorticoids, anti-hypertensives, anti-diabetics, calcium supplements and anti-obesity
        drugs and those who smoke or consume alcohol

        -
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>17 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Senol sentürk, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Recep Tayyip Erdogan University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Recep Tayyip Erdogan University</name>
      <address>
        <city>Rize</city>
        <zip>53000</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>June 12, 2018</study_first_submitted>
  <study_first_submitted_qc>July 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2018</study_first_posted>
  <last_update_submitted>July 13, 2018</last_update_submitted>
  <last_update_submitted_qc>July 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Recep Tayyip Erdogan University Training and Research Hospital</investigator_affiliation>
    <investigator_full_name>Senol Senturk</investigator_full_name>
    <investigator_title>Serum Preptin and Amylin Levels in Polycystic Ovary Syndrome Patients</investigator_title>
  </responsible_party>
  <keyword>amylin; obesity; polycystic ovarian syndrome; preptin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

